How Ezetimibe Lowers Cholesterol
Ezetimibe (brand name Zetia) blocks cholesterol absorption in the small intestine by inhibiting the NPC1L1 protein, reducing dietary and biliary cholesterol uptake by about 50%. It lowers LDL cholesterol by 15-25% as monotherapy.[1]
Ezetimibe vs Statins Like Atorvastatin or Rosuvastatin
Statins inhibit HMG-CoA reductase in the liver, slashing cholesterol synthesis and dropping LDL by 20-60% depending on dose. Ezetimibe alone underperforms statins but adds 15-25% further LDL reduction when combined, as in Vytorin (ezetimibe/simvastatin). Statins cut cardiovascular events more (e.g., 25-35% relative risk reduction in trials like 4S or JUPITER); ezetimibe's IMPROVE-IT trial showed modest event reduction only atop simvastatin.[2][3]
| Drug Class | LDL Reduction (Monotherapy) | CV Event Reduction | Common Side Effects |
|------------|-----------------------------|---------------------|---------------------|
| Ezetimibe | 15-25% | Minimal alone; additive with statins | Diarrhea (4%), fatigue (2%) |
| High-Intensity Statins (e.g., atorva 40-80mg) | 50-60% | 25-35% | Muscle pain (5-10%), liver enzyme rise (1-3%) |
Ezetimibe vs PCSK9 Inhibitors Like Evolocumab or Alirocumab
PCSK9 inhibitors (Repatha, Praluent) are injectables that boost liver LDL receptor recycling, cutting LDL by 50-70%. They outperform ezetimibe in high-risk patients (FOURIER/ODYSSEY trials: 20% CV risk drop). Ezetimibe is oral, cheaper ($10-30/month generic vs $500+/month for PCSK9), and better tolerated but less potent.[4]
Ezetimibe vs Bempedoic Acid or Inclisiran
Bempedoic acid (Nexletol) targets liver cholesterol synthesis like statins but avoids muscle issues, lowering LDL 15-25%—similar to ezetimibe. Inclisiran (Leqvio), an siRNA injection twice yearly, cuts LDL 40-50%. Ezetimibe edges bempedoic in head-to-head LDL drop but pairs better with statins; all three suit statin-intolerant patients.[5]
When Doctors Choose Ezetimibe Over Others
Guidelines (ACC/AHA 2018) recommend ezetimibe as add-on for LDL goals unmet by max statins, before injectables. It's first-line for statin intolerance due to low side-effect profile and oral ease. No diabetes risk like statins; safe in pregnancy (Category C vs statins' X).[6]
Cost and Access Comparison
Generic ezetimibe costs $10-20/month; statins $5-50. PCSK9/bempedoic run $300-6000/month without coverage. Patent on Zetia expired 2017, enabling generics.[7]
[1] Zetia Prescribing Information
[2] IMPROVE-IT Trial, NEJM 2015
[3] JUPITER Trial, NEJM 2008
[4] FOURIER Trial, NEJM 2017
[5] CLEAR Outcomes Trial, NEJM 2023
[6] 2018 ACC/AHA Cholesterol Guideline
[7] DrugPatentWatch.com - Ezetimibe Patents